TARDBP and amyotrophic lateral sclerosis: Indeed, while PET imaging for TDP-43 pathology is not available and detection of pathological TDP-43 in biofluids has yielded conflicting results [28, 40, 41, 46, 69, 79, 86], recent studies show the feasibility of detecting aberrant peptides generated from TDP-43-dependent cryptic splicing in CSF of patients with ALS/FTD [31, 83].